Translational Neuropharmacology Lab
Professor Panos Zanos
Activities
The lab performs preclinical and clinical studies, including drug trials, electroencephalography (EEG), and genetic epidemiology to elucidate mechanisms of neuropsychiatric and neurodegenerative disorders.
Scope
The Translational Neuropharmacology Lab (Zanos Lab) at the University of Cyprus investigates brain disorders through translational neuropharmacology, emphasizing drug repurposing and clinical trials to develop novel therapeutics.
Technologies & Methods
Employs in vitro, ex vivo, and in vivo rodent models, cortical EEG in both rodents and humans, Mendelian Randomization, DNA methylation analysis, and systems bioinformatics to study neurodevelopmental, neurodegenerative, and neuropsychiatric conditions, facilitating innovative drug discovery and therapeutic validation.
Innovation spotlight
The Zanos Lab leads in drug repurposing, notably with Cyprus’ first ketamine trial for opioid use disorder. Ongoing studies utilize EEG to analyze neural activity in smoking cessation and investigate genetic underpinnings of nicotine dependence, leveraging artificial intelligence and bioinformatics to uncover novel therapeutic targets, advancing precision medicine for complex brain disorders. In parallel, we use preclinical models in rodents to understand circuit level changes underlying different brain diseases.
Our laboratory, based in Cyprus, employs molecular and systems neuroscience, behavioral pharmacology, as well as advanced computational methods to unravel the mysteries of brain diseases and identify targets for the development of novel and effective pharmacotherapies.
Projects
For publications click here: